• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Intraday Session

    3/8/23 12:31:16 PM ET
    $AVAH
    $CLXT
    $ETAO
    $HCM
    Medical/Nursing Services
    Health Care
    Agricultural Chemicals
    Industrials
    Get the next $AVAH alert in real time by email

    Gainers

    • LifeStance Health Gr (NASDAQ:LFST) stock increased by 27.2% to $6.03 during Wednesday's regular session. As of 12:30 EST, this security is trading at a volume of 2.7 million shares, making up 683.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $2.2 billion. As per the news, the Q4 earnings report came out today.
    • Mesoblast (NASDAQ:MESO) shares moved upwards by 25.74% to $3.81. Trading volume for this security as of 12:30 EST is 649.6K, which is 453.9% of its average full-day volume over the last 100 days. The company's market cap stands at $561.2 million.
    • Immuneering (NASDAQ:IMRX) shares moved upwards by 21.96% to $6.72. Immuneering's stock is trading at a volume of 66.9K shares as of 12:30 EST. This is 168.9% of its average full-day volume over the last 100 days. The company's market cap stands at $177.4 million. As per the press release, Q4 earnings came out 2 days ago.
    • Kala Pharmaceuticals (NASDAQ:KALA) stock increased by 21.58% to $22.87. Trading volume for Kala Pharmaceuticals's stock is 2.8 million as of 12:30 EST. This is 105.1% of its average full-day volume over the last 100 days. The company's market cap stands at $46.3 million. As per the news, the Q4 earnings report came out 3 days ago.
    • Treace Medical Concepts (NASDAQ:TMCI) shares rose 20.76% to $24.43. Trading volume for Treace Medical Concepts's stock is 621.4K as of 12:30 EST. This is 191.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.4 billion. The company's, Q4 earnings came out yesterday.
    • Aveanna Healthcare Hldgs (NASDAQ:AVAH) stock moved upwards by 20.58% to $1.75. The current volume of 2.5 million shares is 666.6% of Aveanna Healthcare Hldgs's average full-day volume over the last 100 days (last updated at 12:30 EST). The company's market cap stands at $325.0 million.

    Losers

    • Intelligent Bio Solutions (NASDAQ:INBS) shares decreased by 46.7% to $3.16 during Wednesday's regular session. Trading volume for Intelligent Bio Solutions's stock is 371.3K as of 12:30 EST. This is 210.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $2.8 million.
    • Miromatrix Medical (NASDAQ:MIRO) stock fell 38.87% to $1.51. The current volume of 776.8K shares is 3626.8% of Miromatrix Medical's average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $31.5 million.
    • Etao International Co (NASDAQ:ETAO) shares fell 36.06% to $2.04. As of 12:30 EST, this security is trading at a volume of 1.5 million shares, making up 91.1% of its average full-day volume over the last 100 days. The company's market cap stands at $215.6 million.
    • Midatech Pharma (NASDAQ:MTP) stock fell 18.56% to $0.4. As of 12:30 EST, this security is trading at a volume of 119.5K shares, making up 232.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $2.7 million.
    • HUTCHMED (China) (NASDAQ:HCM) stock fell 17.4% to $13.65. The current volume of 671.1K shares is 224.8% of HUTCHMED (China)'s average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $2.3 billion.
    • Calyxt (NASDAQ:CLXT) stock decreased by 16.88% to $0.36. As of 12:30 EST, this security is trading at a volume of 347.7K shares, making up 17.6% of its average full-day volume over the last 100 days. The company's market cap stands at $17.6 million. As per the press release, Q4 earnings came out 4 days ago. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AVAH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVAH
    $CLXT
    $ETAO
    $HCM

    CompanyDatePrice TargetRatingAnalyst
    LifeStance Health Group Inc.
    $LFST
    12/9/2025$8.00Overweight
    Barclays
    Aveanna Healthcare Holdings Inc.
    $AVAH
    12/8/2025Outperform
    William Blair
    Mesoblast Limited
    $MESO
    11/25/2025Hold → Buy
    Jefferies
    LifeStance Health Group Inc.
    $LFST
    11/13/2025$8.00Outperform
    BMO Capital Markets
    Aveanna Healthcare Holdings Inc.
    $AVAH
    11/13/2025$11.00Outperform
    BMO Capital Markets
    Treace Medical Concepts Inc.
    $TMCI
    11/7/2025$5.00Neutral → Underweight
    Analyst
    Treace Medical Concepts Inc.
    $TMCI
    11/7/2025Buy → Neutral
    BTIG Research
    Immuneering Corporation
    $IMRX
    10/31/2025$15.00Outperform
    Leerink Partners
    More analyst ratings

    $AVAH
    $CLXT
    $ETAO
    $HCM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on LifeStance Health Group with a new price target

    Barclays initiated coverage of LifeStance Health Group with a rating of Overweight and set a new price target of $8.00

    12/9/25 8:50:31 AM ET
    $LFST
    Medical/Nursing Services
    Health Care

    William Blair initiated coverage on Aveanna

    William Blair initiated coverage of Aveanna with a rating of Outperform

    12/8/25 8:33:04 AM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    Mesoblast upgraded by Jefferies

    Jefferies upgraded Mesoblast from Hold to Buy

    11/25/25 8:34:05 AM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AVAH
    $CLXT
    $ETAO
    $HCM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Chiu Lorenso

    3 - HUTCHMED (China) Ltd (0001648257) (Issuer)

    3/18/26 5:52:27 PM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Krause Philip R.

    3 - MESOBLAST LTD (0001345099) (Issuer)

    3/18/26 5:44:56 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Weil Samuel Altman

    3 - Aveanna Healthcare Holdings, Inc. (0001832332) (Issuer)

    3/18/26 5:30:07 PM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    $AVAH
    $CLXT
    $ETAO
    $HCM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Business Officer Brakewood Harold Eugene bought $24,990 worth of shares (5,250 units at $4.76), increasing direct ownership by 91% to 11,050 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    1/21/26 9:09:57 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Schall Thomas J. bought $101,041 worth of shares (21,645 units at $4.67), increasing direct ownership by 41% to 74,530 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    1/20/26 9:17:29 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF SCIENTIFIC OFFICER Hall Brett Matthew bought $10,502 worth of shares (2,298 units at $4.57), increasing direct ownership by 0.61% to 376,496 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    1/16/26 4:07:43 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVAH
    $CLXT
    $ETAO
    $HCM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aveanna Healthcare Holdings Announces Fourth Quarter and Full Year 2025 Financial Results

    Fourth Quarter Revenue was $662.5 million, a 27.4% increase over the prior year periodFourth Quarter Net income was $178.8 million compared to $29.2 million for the prior year periodAdjusted EBITDA for Q4 2025 was $85.0 million, a 54.0% increase over the prior year periodMaintained Full Year 2026 Revenue guidance of between $2.54 and $2.56 billion Maintained Full Year 2026 Adjusted EBITDA guidance of between $318 and $322 million Announced agreement to acquire Family First Homecare subsequent to the Fourth Quarter ATLANTA, March 19, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH), a leading, diversified home care platform focused on providing care to medically comp

    3/19/26 7:00:00 AM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    Red Light Holland Engages Kala Bio's Researgency.AI Platform to Support Clinical Development of Filament's Patented PEX010 Botanical Psilocybin Drug Candidate

    AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio's purpose-built agentic AI platform for the biotechnology industry TORONTO and ARLINGTON, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Red Light Holland Corp. (CSE:TRIP) (FSE: 4YX) (OTCQB:TRUFF) ("Red Light" or the "Company") and Kala Bio, Inc. (NASDAQ:KALA) ("Kala Bio") today announced that Red Light has engaged Kala Bio's with its Researgency.ai agentic artificial intelligence platform under world wide license from Younet to support the clinical development strategy for PEX010, the patented botanical psilocybin drug candidate originated by Filament Health Corp. ("Fil

    3/18/26 9:00:00 AM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mesoblast to Host R&D Day on April 8, 2026

    NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, will host its inaugural R&D Day on Wednesday, April 8, 2026 in New York City. The event will be webcast live from 8:00am to 11:00am EST and will include presentations from Mesoblast's senior leadership team and from key opinion leaders. The event will include discussions regarding the company's corporate strategy, successful commercialization of its flagship product Ryoncil®, and its robust multi-billion-dollar pipeline opportunities in inflammatory pain and cardiovascular disease. In addition, the company will unveil new technol

    3/17/26 7:19:57 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AVAH
    $CLXT
    $ETAO
    $HCM
    SEC Filings

    View All

    Aveanna Healthcare Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Aveanna Healthcare Holdings, Inc. (0001832332) (Filer)

    3/19/26 7:00:10 AM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    SEC Form 6-K filed by Mesoblast Limited

    6-K - MESOBLAST LTD (0001345099) (Filer)

    3/18/26 6:53:53 AM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form D filed by KALA BIO Inc.

    D - KALA BIO, Inc. (0001479419) (Filer)

    3/17/26 4:59:15 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVAH
    $CLXT
    $ETAO
    $HCM
    Leadership Updates

    Live Leadership Updates

    View All

    Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast

    NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the appointment of Teresa Montagut MD, PhD in the newly established position of Head of Clinical Development and Medical Affairs reporting to the Chief Medical Officer Dr. Eric Rose. In this role, Teresa will lead Mesoblast's medical affairs organization, fostering clinical collaborations and spearheading investigator-initiated trials, enhancing clinical and medical communications, and engaging with healthcare professionals. She will play a critical role in unlocking the value of Mesoblast's cell therapy programs i

    3/11/26 7:21:39 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:​HCM, HKEX:​13) today announces that Professor Tan Shao Weng, Daniel (Chen Shaowen) is appointed as an Independent Non-executive Director and a member of the Technical Committee of the Company with effect from October 15, 2025. Professor Tan, aged 47, has over 20 years of experience in oncology, with his main research interests focusing on thoracic, head and neck malignancies, and drug development. He is the head of the Division of Clinical Trials and Epidemiological Sciences and a senior consultant in the Division of Medical Oncology at the N

    10/14/25 4:30:00 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Appoints Dr. Thomas Schall as Chairman of the Board

    NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the appointment of Thomas J. Schall, Ph.D., to Chairman of the Board of Directors. Dr. Schall is a renowned biotech executive and scientist with more than 30 years of leadership in drug discovery and development. He is best known as the founder and longtime CEO and Chairman of ChemoCentryx, where he led the development and eventual FDA approval of Tavneos®, a first-in-class oral therapy for ANCA-associated vasculitis. Under his leadership, ChemoCentryx was acquired by Amgen in 2022 for nearly $4 billion. His career

    9/16/25 7:00:00 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVAH
    $CLXT
    $ETAO
    $HCM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mesoblast Limited

    SC 13G/A - MESOBLAST LTD (0001345099) (Subject)

    12/16/24 12:08:07 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Intelligent Bio Solutions Inc.

    SC 13G/A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)

    11/14/24 7:16:17 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by KALA BIO Inc.

    SC 13G - KALA BIO, Inc. (0001479419) (Subject)

    11/14/24 4:49:42 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVAH
    $CLXT
    $ETAO
    $HCM
    Financials

    Live finance-specific insights

    View All

    Aveanna Healthcare Holdings Announces Fourth Quarter and Full Year 2025 Financial Results

    Fourth Quarter Revenue was $662.5 million, a 27.4% increase over the prior year periodFourth Quarter Net income was $178.8 million compared to $29.2 million for the prior year periodAdjusted EBITDA for Q4 2025 was $85.0 million, a 54.0% increase over the prior year periodMaintained Full Year 2026 Revenue guidance of between $2.54 and $2.56 billion Maintained Full Year 2026 Adjusted EBITDA guidance of between $318 and $322 million Announced agreement to acquire Family First Homecare subsequent to the Fourth Quarter ATLANTA, March 19, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH), a leading, diversified home care platform focused on providing care to medically comp

    3/19/26 7:00:00 AM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    Treace Medical Concepts Reports Fourth Quarter and Full-Year 2025 Financial Results

    PONTE VEDRA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today reported financial results for the fourth quarter and full-year ended December 31, 2025. Recent Highlights Generated revenue of $62.5 million in fourth quarter 2025 and revenue of $212.7 million for the full-year 2025, an increase of 2% compared to the prior year.Reported fourth quarter 2025 net loss of $(9.4) million and adjusted EBITDA of $6.2 million in the fourth quarter 2025. Reported full-year 2025 net loss of $(59.0) million c

    2/27/26 7:05:00 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Aveanna Announces Fourth Quarter and Full Year 2025 Earnings Release Date and Conference Call

    ATLANTA, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. ("Aveanna") (NASDAQ:AVAH) today announced that the company will release its fourth quarter and full year results before the market open on Thursday, March 19, 2026, to be followed by a conference call at 10:00 a.m. (Eastern Time) on the same day. The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available three hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 13757396. The replay will be available until March

    2/26/26 6:30:00 AM ET
    $AVAH
    Medical/Nursing Services
    Health Care